Opinion|Videos|May 16, 2024
Future Perspectives on Schizophrenia Care
John M. Kane, MD, and Erin Crown, PA-C, CAQ-Psychiatry, provide closing thoughts on improving schizophrenia care in the future, highlighting the importance of personalizing treatment, shared decision-making, treatment recommendations, and keeping patients engaged.
Advertisement
Episodes in this series
Advertisement
Related to this article
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
2
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
3
Searching for a New TMS Target in Schizophrenia, With Andrew Pines, MD
4
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
5